AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of ARS 367.58 trillion. The enterprise value is 403.55 trillion.
| Market Cap | 367.58T |
| Enterprise Value | 403.55T |
Important Dates
The next estimated earnings date is Thursday, November 6, 2025.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | Aug 8, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.06% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 37.19 and the forward PE ratio is 16.77.
| PE Ratio | 37.19 |
| Forward PE | 16.77 |
| PS Ratio | 5.46 |
| PB Ratio | 6.88 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 27.60 |
| P/OCF Ratio | 23.04 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.96, with an EV/FCF ratio of 30.30.
| EV / Earnings | 40.82 |
| EV / Sales | 5.15 |
| EV / EBITDA | 14.96 |
| EV / EBIT | 20.30 |
| EV / FCF | 30.30 |
Financial Position
The company has a current ratio of 0.86, with a Debt / Equity ratio of 0.74.
| Current Ratio | 0.86 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 2.95 |
| Interest Coverage | 10.77 |
Financial Efficiency
Return on equity (ROE) is 19.67% and return on invested capital (ROIC) is 11.88%.
| Return on Equity (ROE) | 19.67% |
| Return on Assets (ROA) | 8.28% |
| Return on Invested Capital (ROIC) | 11.88% |
| Return on Capital Employed (ROCE) | 18.19% |
| Revenue Per Employee | 714.02M |
| Profits Per Employee | 104.83M |
| Employee Count | 94,300 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.65 |
Taxes
In the past 12 months, AstraZeneca has paid 2.05 trillion in taxes.
| Income Tax | 2.05T |
| Effective Tax Rate | 17.17% |
Stock Price Statistics
The stock price has increased by +44.96% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +44.96% |
| 50-Day Moving Average | 59,485.00 |
| 200-Day Moving Average | 48,001.50 |
| Relative Strength Index (RSI) | 50.46 |
| Average Volume (20 Days) | 862 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of ARS 67.33 trillion and earned 9.89 trillion in profits. Earnings per share was 6,326.07.
| Revenue | 67.33T |
| Gross Profit | 55.39T |
| Operating Income | 17.10T |
| Pretax Income | 11.94T |
| Net Income | 9.89T |
| EBITDA | 22.79T |
| EBIT | 17.10T |
| Earnings Per Share (EPS) | 6,326.07 |
Balance Sheet
The company has 8.47 trillion in cash and 39.25 trillion in debt, giving a net cash position of -30,782.80 billion.
| Cash & Cash Equivalents | 8.47T |
| Total Debt | 39.25T |
| Net Cash | -30,782.80B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 53.40T |
| Book Value Per Share | 34,381.70 |
| Working Capital | -5,478.24B |
Cash Flow
In the last 12 months, operating cash flow was 15.96 trillion and capital expenditures -2,637.23 billion, giving a free cash flow of 13.32 trillion.
| Operating Cash Flow | 15.96T |
| Capital Expenditures | -2,637.23B |
| Free Cash Flow | 13.32T |
| FCF Per Share | n/a |
Margins
Gross margin is 82.26%, with operating and profit margins of 25.40% and 14.68%.
| Gross Margin | 82.26% |
| Operating Margin | 25.40% |
| Pretax Margin | 17.74% |
| Profit Margin | 14.68% |
| EBITDA Margin | 33.85% |
| EBIT Margin | 25.40% |
| FCF Margin | 19.78% |
Dividends & Yields
This stock pays an annual dividend of 795.69, which amounts to a dividend yield of 1.30%.
| Dividend Per Share | 795.69 |
| Dividend Yield | 1.30% |
| Dividend Growth (YoY) | 39.02% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 59.51% |
| Buyback Yield | -0.06% |
| Shareholder Yield | 1.24% |
| Earnings Yield | 2.69% |
| FCF Yield | 3.62% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 6 |